| Genetics and molecular epidemiology of multiple myeloma: The rationale for the IMMEnSE consortium (Review) |
Authors: Alessandro Martino, Juan Sainz, Gabriele Buda, Krzysztof Jamroziak, Rui Manuel Reis, Ramón García-Sanz, Manuel Jurado, Rafael Ríos, Zofia Szemraj-Rogucka, Herlander Marques, Fabienne Lesueur, Victor Moreno, Enrico Orciuolo, Federica Gemignani, Stefano Landi, Anna Maria Rossi, Charles Dumontet, Mario Petrini, Daniele Campa, Federico Canzian |
Affiliations: German Cancer Research Center (DKFZ), Genomic Epidemiology Group, Im Neuenheimer Feld 580, D-69120 Heidelberg, Germany |
Published online on: Tuesday, December 6, 2011 |
Doi: 10.3892/ijo.2011.1284 |
Pages: 625-638 |
Abstract:There is strong evidence suggesting the presence of a genetic component in the aetiology of multiple myeloma (MM). However no genetic risk factors have been unequivocally established so far. To further our understanding of the genetic determinants of MM risk, a promising strategy is to collect a large set of patients in a consortium, as successfully done for other cancers. In this article, we review the main findings in the genetic susceptibility and pharmacogenetics of MM and present the strategy of the IMMEnSE (International Multiple Myeloma rESEarch) consortium in contributing to determine the role of genetic variation in pharmacogenetics and in MM risk. |
|
|
|
|
